De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Johnson & Johnson Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Johnson & Johnson heeft een totaal eigen vermogen van $71.5B en een totale schuld van $41.5B, wat de schuld-eigenvermogensverhouding op 58% brengt. De totale activa en totale passiva bedragen respectievelijk $181.1B en $109.6B. De EBIT Johnson & Johnson is $24.2B waardoor de rentedekking -33.2 is. Het heeft contanten en kortetermijnbeleggingen van $25.5B.

Belangrijke informatie

58.0%

Verhouding schuld/eigen vermogen

US$41.49b

Schuld

Rente dekkingsratio	-33.2x
Contant	US$25.48b
Aandelen	US$71.54b
Totaal verplichtingen	US$109.55b
Totaal activa	US$181.09b

Recente financiële gezondheidsupdates

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Aug 23

Recent updates

Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction

Jul 03

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $57.8B ) JNJ } overtreffen de korte termijn passiva ( $53.9B ).

Langlopende schulden: De kortetermijnactiva JNJ ( $57.8B ) overtreffen de langetermijnschulden ( $55.6B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 22.4% ) JNJ wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van JNJ is de afgelopen 5 jaar gestegen van 48.4% naar 58%.

Schuldendekking: De schuld van JNJ wordt goed gedekt door de operationele kasstroom ( 59.4% ).

Rentedekking: JNJ verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Johnson & Johnson Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Recent updates

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson: A Sell-Rated Dividend King

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Johnson & Johnson: Don't Bet Against Double Compounding

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib)

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Results from the Phase 2 Open-Label UNITY Study of Nipocalimab for the Treatment of Alloimmunized Pregnant Individuals

Johnson & Johnson Announces Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible

Consensus EPS estimates fall by 10%

Johnson & Johnson Seeks U.S. FDA Approval of Spravato (Esketamine) as the First and Only Monotherapy for Adults with Treatment-Resistant Depression

Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024

Johnson & Johnson Q2: Robust New Product Pipeline

Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024

Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality

Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction

Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI

Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven